|
|
Blood, 1 March 2005, Vol. 105, No. 5, pp. 2090-2092.
Prepublished online as a Blood First Edition Paper on November 4, 2004; DOI 10.1182/blood-2004-09-3579.
 Previous Article | Table of Contents | Next Article 
IMMUNOBIOLOGY
Brief report
Immunotherapy of autoimmune encephalomyelitis with redirected CD4+CD25+ T lymphocytes
Divya J. Mekala, and
Terrence L. Geiger
From the Department of Pathology, St Jude Children's Research Hospital, Memphis, TN.
We developed an approach that increases CD4+CD25+ regulatory T-cell potency by antigen-specifically redirecting them against pathologic T lymphocytes. The regulatory cells are transgenically modified with chimeric receptors that link antigen–major histocompatibility complex (MHC) extracellular and transmembrane domains with the cytoplasmic signaling tail of T-cell receptor  (TCR-). The receptors' antigen-MHC recognizes the TCR of cognate T lymphocytes. Receptor engagement stimulates the receptor-modified T cell (RMTC) through the linked chain. CD4+CD25+ RMTCs expressing a myelin basic protein (MBP) 89-101-IAs- receptor, unlike unmodified CD4+CD25+ T cells or CD4+CD25- RMTCs, prevented and treated experimental allergic encephalomyelitis (EAE) induced with MBP89-101. The RMTCs were effective even after the autoreactive T-cell repertoire had diversified to include specificities not directly targeted by the chimeric receptor. Remissions were sustained and mortality was decreased from more than 50% to 0%. These results provide proof of principal for a novel approach to enforce the interaction of regulatory and pathologic T lymphocytes, thereby facilitating the treatment of autoimmune disease.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
R. K. Selvaraj and T. L. Geiger
Mitigation of Experimental Allergic Encephalomyelitis by TGF-{beta} Induced Foxp3+ Regulatory T Lymphocytes through the Induction of Anergy and Infectious Tolerance
J. Immunol.,
March 1, 2008;
180(5):
2830 - 2838.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
I. Moisini, P. Nguyen, L. Fugger, and T. L. Geiger
Redirecting Therapeutic T Cells against Myelin-Specific T Lymphocytes Using a Humanized Myelin Basic Protein-HLA-DR2-{zeta} Chimeric Receptor
J. Immunol.,
March 1, 2008;
180(5):
3601 - 3611.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
R. K. Selvaraj and T. L. Geiger
A Kinetic and Dynamic Analysis of Foxp3 Induced in T Cells by TGF-beta
J. Immunol.,
June 15, 2007;
178(12):
7667 - 7677.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
A. Mor, G. Luboshits, D. Planer, G. Keren, and J. George
Altered status of CD4+CD25+ regulatory T cells in patients with acute coronary syndromes
Eur. Heart J.,
November 1, 2006;
27(21):
2530 - 2537.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. J. Scalapino, Q. Tang, J. A. Bluestone, M. L. Bonyhadi, and D. I. Daikh
Suppression of Disease in New Zealand Black/New Zealand White Lupus-Prone Mice by Adoptive Transfer of Ex Vivo Expanded Regulatory T Cells
J. Immunol.,
August 1, 2006;
177(3):
1451 - 1459.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Mekala, R. S. Alli, and T. L. Geiger
IL-10-dependent infectious tolerance after the treatment of experimental allergic encephalomyelitis with redirected CD4+CD25+ T lymphocytes
PNAS,
August 16, 2005;
102(33):
11817 - 11822.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
